Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer

1 Jan 2020

Abstract excerpt

OBJECTIVE: Precision oncology depends on translating molecular data into therapy recommendations. However, with the growing complexity of next-generation sequencing-based tests, clinical interpretation of somatic genomic mutations has evolved into a formidable task. Here, we compared the performance of three commercial clinical decision support tools, that is, NAVIFY Mutation Profiler (NAVIFY; Roche), QIAGEN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Genomics and Rare Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32967919
DOI: 10.1136/esmoopen-2020-000872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancerPMID 32967919Read ↗

Assessment of a Highly Curated Somatic Oncology Database to Aid in the Interpretation of Clinically Important Variants in Next-Generation Sequencing Results.Semantic proximity Read ↗

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.Semantic proximity Read ↗

Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology ProgramSemantic proximity Read ↗

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.Semantic proximity Read ↗

Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.Semantic proximity Read ↗

Clinical interpretation of integrative molecular profiles to guide precision cancer medicineSemantic proximity Read ↗

MatchMiner: An open source computational platform for real-time matching of cancer patients to precision medicine clinical trials using genomic and clinical criteriaSemantic proximity Read ↗

Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.